DDX53 and neoplasm: We confirmed the superiority of the Vox+anti-PD-1 antibody combination by comparing in the GFP-Luc-CT26 CRC-PM model, the tumor burden (PCI score) (figure 2D) and survival (figure 2E) in the different treatment groups.